Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 2/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | TP53BP1 | Q12888 | 1/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.41 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.41 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA5A | P35218 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30673452 | 1.00 | CYP2C19 (0.50) | CYP2C19HIF1ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL6585600 | 0.87 | KMT2A (0.40) | CYP2C19HIF1ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL16081706 | 0.85 | PARP1 (0.44) | CYP2C19HIF1ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL21981929 | 0.83 | CYP2C19 (0.47) | CYP2C19HIF1ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL21981930 | 0.83 | CYP2C19 (0.47) | CYP2C19HIF1ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL23773695 | 0.82 | CYP2C19 (0.53) | CYP2C19HIF1AHDAC3HDAC4HDAC2 | |
| SCHEMBL22111154 | 0.82 | GAA (0.43) | SMN1; SMN2MEN1KMT2ATP53BP1HDAC3 | |
| SCHEMBL20669809 | 0.82 | MEN1 (0.42) | CYP2C19SMN1; SMN2MEN1KMT2ATP53BP1 | |
| SCHEMBL1492520 | 0.82 | CA1 (0.44) | CYP2C19HIF1ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL21200581 | 0.81 | GAA (0.42) | SMN1; SMN2MEN1KMT2ATP53BP1HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260034111-A1 | NOVEL HETEROCYCLES AS sPLA2-X INHIBITORS | CAYMAN CHEMICAL COMPANY INCORPORATED (US) | 2026-02-05 | — | — | US | disclosed |
| WO-2025243317-A1 | SUBSTITUTED BICYCLIC SULFONAMIDE DERIVATIVES AS MODULATORS OF CBL-B | JUBILANT BIOSYS LIMITED (IN) | 2025-11-27 | — | — | WO | disclosed |
| EP-4573085-A1 | SUBSTITUTED PYRIDINONE COMPOUNDS AS CBL-B INHIBITORS | Glenmark Pharmaceuticals Limited (IN) | 2025-06-25 | — | — | EP | disclosed |
| EP-4561991-A1 | NOVEL HETEROCYCLES AS SPLA2-X INHIBITORS | Cayman Chemical Company, Inc. (US) | 2025-06-04 | — | — | EP | disclosed |
| US-12303544-B2 | Cytotoxic and anti-mitotic compounds, and methods of using the same | ZYMEWORKS BC INC. (CA) | 2025-05-20 | — | — | US | disclosed |
| CN-119546587-A | Substituted pyridone compounds as CBL-B inhibitors | 格兰玛克制药有限公司 | 2025-02-28 | — | — | CN | disclosed |
| CN-113631168-B | GPR35 modulators | 普罗米修斯生物科学公司 | 2024-11-19 | — | — | CN | disclosed |
| US-20240254163-A1 | HEMIASTERLIN DERIVATIVES FOR CONJUGATION AND THERAPY | SUTRO BIOPHARMA, INC. | 2024-08-01 | — | — | US | disclosed |
| EP-3914256-B1 | GPR35 MODULATORS | PROMETHEUS BIOSCIENCES INC (US) | 2024-05-29 | — | — | EP | disclosed |
| WO-2024062363-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS AS CBL-B INHIBITORS | GLENMARK PHARMACEUTICALS LTD (IN) | 2024-03-28 | — | — | WO | disclosed |
| US-20160257709-A1 | HEMIASTERLIN DERIVATIVES FOR CONJUGATION AND THERAPY | SUTRO BIOPHARMA, INC. | 2016-09-08 | — | — | US | disclosed |
| US-20160257709-A1 | HEMIASTERLIN DERIVATIVES FOR CONJUGATION AND THERAPY | SUTRO BIOPHARMA, INC. | 2016-09-08 | — | — | US | disclosed |
| US-20160257709-A1 | HEMIASTERLIN DERIVATIVES FOR CONJUGATION AND THERAPY | SUTRO BIOPHARMA, INC. | 2016-09-08 | — | — | US | disclosed |
| WO-2016123582-A1 | HEMIASTERLIN DERIVATIVES FOR CONJUGATION AND THERAPY | SUTRO BIOPHARMA, INC. (US) | 2016-08-04 | — | — | WO | disclosed |
| WO-2016123582-A1 | HEMIASTERLIN DERIVATIVES FOR CONJUGATION AND THERAPY | SUTRO BIOPHARMA, INC. (US) | 2016-08-04 | — | — | WO | disclosed |
| CN-105358174-A | Cytotoxic and antimitotic compounds and methods of use thereof | CT FOR DRUG RES AND DEV | 2016-02-24 | — | — | CN | disclosed |
| US-20160038606-A1 | CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME | ZYMEWORKS BC INC. (CA) | 2016-02-11 | — | — | US | disclosed |
| WO-2015095952-A1 | VAR2CSA-DRUG CONJUGATES | THE CENTRE FOR DRUG RESEARCH AND DEVELOPMENT (CA) | 2015-07-02 | — | — | WO | disclosed |
| US-20140315954-A1 | CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME | ZYMEWORKS BC INC. (CA) | 2014-10-23 | — | — | US | disclosed |
| US-20140315954-A1 | CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME | ZYMEWORKS BC INC. (CA) | 2014-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260034111-A1 | NOVEL HETEROCYCLES AS sPLA2-X INHIBITORS | PLA2G2F, PLA2R1, PLA2G12A | CYP2C19 1906/4885HIF1A 3298/4885SMN1; SMN2 1439/4885 |
| US-20140315954-A1 | CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME | CCNB1, CCNB2, CCNB3 | CYP2C19 2717/4885HIF1A 4809/4885SMN1; SMN2 773/4885 |
| US-20240254163-A1 | HEMIASTERLIN DERIVATIVES FOR CONJUGATION AND THERAPY | CYP17A1, HSD17B7, SHBG | CYP2C19 2167/4885HIF1A 2600/4885SMN1; SMN2 2005/4885 |
| US-20160257709-A1 | HEMIASTERLIN DERIVATIVES FOR CONJUGATION AND THERAPY | CYP17A1, HSD17B7, SHBG | CYP2C19 2167/4885HIF1A 2600/4885SMN1; SMN2 2005/4885 |
| US-12303544-B2 | Cytotoxic and anti-mitotic compounds, and methods of using the same | CCNB1, PLK1, BOD1L1 | CYP2C19 4458/4885HIF1A 4754/4885SMN1; SMN2 860/4885 |
| US-20160038606-A1 | CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME | CCNB1, PLK1, CCNB2 | CYP2C19 4440/4885HIF1A 4717/4885SMN1; SMN2 858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.